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Abstract  
A recent study has identified gene mutations involving the MAPK/ERK pathway, 
particularly the HRAS gene, in all inverted urothelial papillomas, in the absence of 
pathway mutations in TERT promoter, FGFR3, and TP53/RB1genes. Neither recurrence 
nor progression was observed in inverted urothelial papillomas. These data support 
several longstanding hypotheses: 1) inverted urothelial papillomas are benign and do 
not recur or progress; 2) they harbor mutations that are different from those of urothelial 
carcinoma; and 3) they arise through different molecular mechanisms than low- or high-
grade urothelial carcinoma. As the most critical differential diagnosis in this context is 
inverted-type urothelial carcinoma, more comprehensive studies are needed to compare 
and contrast these entities. 
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Inverted urothelial papilloma (IUP) is a rare (<1% of bladder neoplasms) neoplasm 
characterized by inverted growth of anastomosing nests and cords of cytologically bland 
urothelial cells and peripherally palisading basal cells. Differential diagnosis includes a 
wide spectrum of nonneoplastic and neoplastic urothelial proliferations with an 
endophytic growth pattern, such as florid cystitis cystica et glandularis, inverted 
papillary urothelial neoplasm of low malignant potential, large nested variant urothelial 
carcinoma, and noninvasive low- and high-grade papillary urothelial carcinomas with 
inverted growth [1]. Although the diagnosis of IUP could be challenging, up to 25% of 
cases of inverted urothelial carcinoma may be misdiagnosed as IUP, highlighting the 
difficulty of morphologically distinguishing these entities in some instances. 
 Urothelial papilloma (UP) represents the least cytologically and architecturally 
atypical member of the papillary urothelial neoplasms of the urinary tract. In urothelial 
papilloma, delicate fibrovascular cores are lined by several layers of urothelial cells 
preserving polarity and lacking atypia [1]. When using strict criteria designated by the 
World Health Organization (WHO), both entities account for less than 1% of papillary 
urothelial neoplasms.  
Urothelial carcinoma has two main oncogenic pathways. FGFR3 mutations are 
frequently associated with low-grade noninvasive urothelial carcinoma (Figure 1), and 
the TP53 pathway, in contrast, is associated with high-grade invasive cancer [2]. 
Moreover, about 70-80% of noninvasive urothelial carcinomas harbor promoter 
mutations in the TERT gene, especially concurrent with FGFR3 mutations. FGFR3 
mutations might have therapeutic implications, considering the recent approval of 
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erdafitinib, a new FGFR2/FGFR3 inhibitor, for clinical use in patients with locally 
advanced or metastatic bladder cancer that is unresponsive to platinum-based 
chemotherapy [3]. STAG2 and PIK3CA mutations are also frequently described in 
noninvasive urothelial carcinoma and are seen in approximately 33% and 25% of the 
cases, respectively [2]. 
Several groups of investigators, using cohorts of various size and a variety of 
methodologies, have studied the genomic landscape of IUP (Table 1) [4-9]. In a recent 
issue of The Journal of Pathology, Isharwal and colleagues reported the findings from 
the most recent of such efforts. Their study, using next generation sequencing on IUPs 
and (urothelial papillomas) UPs, employing the MSK-IMPACT platform targeting 486 
cancer associated genes, as well as whole exome sequencing in a subset of cases, is by 
far the most comprehensive study to date [9].  
All IUPs and UPs had mutations in the MAPK/ERK pathway, HRAS and KRAS 
mutations being predominant in IUPs (10/11) and UPs (8/11), respectively. None of the 
IUPs and UPs had an APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-
like) mutational signature, which was identified in about 70% of muscle-invasive 
urothelial carcinomas [10], and all had low mutational burden. The vast majority of 
IUPs and UPs did not show mutations in FGFR3, TERT, TP53, RB1, or chromatin 
remodeling genes, which are known to be common mutations in urothelial carcinoma.  
Urothelial carcinomas with HRAS/KRAS mutations also seem to have enriched 
mutations at the TERT promoter region as well as mutations at various TP53/cell cycle 
genes. It has been observed repeatedly that mutations at the FGFR3, PI3KCA and TERT 
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genes are present in the majority of the low-grade urothelial carcinomas, whereas 
mutations involving the MAPK/ERK pathway, mainly HRAS, KRAS and occasionally 
BRAF, have been identified in UPs and IUPs [8-9]. In the current study, all IUPs (10 
HRAS and 1 KRAS mutations) and 91% of UPs (8 KRAS and 2 HRAS) had MAPK/ERK 
pathway mutations and no papilloma harbored TP53 mutations [9]. The findings in the 
current study are comparable to those of a previous study [8]. One shortcoming of the 
current study is the absence of a clear comparison of the mutational status between IUP 
and inverted noninvasive urothelial carcinoma. Another limitation is the small sample 
size which may explain why certain mutations may not be detected in contrast to other 
studies.  
In summary, the current study provides evidence for the hypothesis that IUPs 
and UPs harbor mutations that are different from those of urothelial carcinoma, and 
arise through molecular mechanisms that are different from those of low- or high-grade 
urothelial carcinoma (Figure 1). Additional comprehensive studies to delineate the 
nature of IUP and to further clarify the molecular differences between IUP and inverted 
urothelial carcinoma are warranted. 
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Figure Legend 
Figure 1. Activating mutations targeting various proteins forming MAPK/ERK and 
PI3KCA signaling pathways are commonly detected in low-grade urothelial neoplasms. 
These mutations cause stimulation at different genomic sites, including FGFR3 and/or 
its receptor-linked tyrosine kinases, downstream proteins such as RAS (particularly 
HRAS and KRAS), and occasionally RAF (BRAF). The PI3CKA/AKT pathway is also 
coupled with the receptor tyrosine kinase complex and directly interacts with the 
MAPK/ERK pathway. Activation of both pathways results in nuclear transcription of 
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proteins that play a role in cell growth, cell cycle progression, and proliferation. Another 
frequently mutated gene, TERT, causes perpetual activation of the TERT enzyme and 
alters the delicate balance of telomere maintenance. Increased telomerase activity helps 
the neoplastic cells become immortal by avoiding the natural occurrence of telomere 
shortening, cell cycle arrest/senescence, and cell death.  
   Indicates proteins in which their associated genes are targeted by activating 
mutations in low grade urothelial carcinoma; 
   Indicates proteins in which their associated genes are targeted by activating 
mutations in urothelial papilloma and inverted urothelial papilloma 
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Table 1. Molecular studies investigating inverted urothelial papilloma (IUP)
Citation Number 
of cases
Age
(range)
Gender 
M/F
Test used Genes 
included
Findings 
[7] 39 N/A 36/3 LOH NA 3/37 D9S177, 4/38 
TP53, 3/37 IFNA, 
3/36 D3S1300
[6] 20 58
(37-75)
18/2 Sanger 
sequencing 
FGFR3 (exon 7, 
10, 15), TP53 
(exons 5,7,8)
9/20 FGFR3 
mutations (most 
common exon 7), 
none had TP53 
mutations 
[11]* 26 N/A N/A FISH Telomere length 5/26 IUPs, 26/26 
inverted TCC had 
telomere shortening 
[8]† 5 59
(50-74)
5/0 NGS/Sanger 
sequencing 
50 gene panel 3/5 HRAS, 1/5 
FGFR3
[5]*† 26 59
(35-74)
22/4 Sanger 
sequencing 
TERT promoter 4/26TERT mutations
[9]* 11 66
(53-90)
9/2 Whole exome 
sequencing/NGS
486 gene panel 10/11 HRAS, 1/11 
KRAS 
*Cases including urothelial carcinoma for comparison
†Cases including inverted urothelial carcinoma
FISH: fluorescence in situ hybridization; LOH, loss of heterozygosity; NGS, next generation 
sequencing; IUP, inverted urothelial papilloma; TCC, transitional cell (urothelial) carcinoma
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